Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
NCT02275156
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperlipidemia
Mixed Dyslipidemia
Interventions
BIOLOGICAL:
Evolocumab
Sponsor
Amgen